Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year ...

The Business Research Company's Prurigo Nodularis Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Latest Report Explores ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on ...

Nemolizumab provides significant relief from itch and skin lesions in prurigo nodularis and atopic dermatitis, with sustained efficacy over two years. The biologic targets the interleukin-31 ...

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis ...

Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...